Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jcin.2021.04.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Outcomes Following Low-Dose Second-Generation "Ranger" Drug-Coated Balloon Angioplasty for Femoropopliteal Artery Disease.
J Endovasc Ther
November 2024
Department of Cardiology, Kishiwada Tokushukai Hospital, Kishiwada, Japan.
Purpose: To reveal the rate of 1-year freedom from restenosis and to determine the factors associated with the restenosis risk in femoropopliteal (FP) lesions treated with a Ranger drug-coated balloon (DCB) in real-world clinical settings.
Methods: This multicenter, prospective observational study enrolled 1131 patients and 1453 de novo or restenotic FP lesions (mean age=75±9 years; female=35.3%, mean lesion length=19.
Low-Dose vs High-Dose Drug-Coated Balloon for Symptomatic Femoropopliteal Artery Disease: The PROSPECT MONSTER Study Outcomes.
JACC Cardiovasc Interv
November 2023
Division of Vascular Surgery, Department of Surgery, Jikei University School of Medicine, Tokyo, Japan.
Background: Randomized trials have shown comparable outcomes between second-generation low-dose drug-coated balloons (LD-DCBs) and first-generation high-dose drug-coated balloons (HD-DCBs); but the trial patients had low clinical complexity, and there were no comparisons in medically complex populations.
Objectives: The aim of this study was to compare outcomes between an LD-DCB (Ranger; 2.0 μg/mm) and an HD-DCB (IN.
Differences in Biologic Drug Effects and Distal Particulate Embolization in Three Paclitaxel-Coated Balloons for Femoropopliteal Lesions in a Rabbit Model.
J Endovasc Ther
December 2024
Department of Cardiology, Tokai University School of Medicine, Isehara, Japan.
Article Synopsis
- A recent study found that patients treated with high-dose drug-coated balloons (DCBs) had a higher risk of major amputations compared to standard treatments, prompting research into the effects of different DCBs on drug delivery and embolization.
- The study involved testing three types of DCBs in rabbits, measuring paclitaxel concentrations and evaluating tissue changes after 28 days.
- Results showed that the Ranger DCB had the highest paclitaxel concentration and caused the most severe tissue damage, while the Lutonix DCB resulted in lower drug concentration in distal muscles but fewer downstream effects.
Low-Dose vs High-Dose Paclitaxel-Coated Balloons for Femoropopliteal Lesions: 2-Year Results From the COMPARE Trial.
JACC Cardiovasc Interv
October 2022
Division of Angiology, Department of Internal Medicine, Neurology and Dermatology, University Hospital Leipzig, Leipzig, Germany. Electronic address:
Background: So far only 1-year data have been reported for direct comparisons of paclitaxel-coated balloons (PCBs) using different coating technologies.
Objectives: The aim of this study was to report the 24-month results on the efficacy and safety of low-dose vs high-dose PCBs with nominal paclitaxel densities of 2.0 and 3.
The Ranger "Low-Dose" Paclitaxel Drug-Coated Balloon: Is Less Really More?
JACC Cardiovasc Interv
May 2021
Department of Cardiology, Prairie Heart Institute at St. John's Hospital, Springfield, Illinois, USA. Electronic address:
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!